Literature DB >> 3593904

Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships.

G J Szpunar, K S Albert, G G Bole, J N Dreyfus, G F Lockwood, J G Wagner.   

Abstract

Flurbiprofen pharmacokinetics were studied in 15 normal male subjects after four oral doses. Plasma levels of total (bound + free) drug were monitored for 48 h and urine was collected for 96 h after the doses. All subjects demonstrated linear relationships between administered dose and total flurbiprofen AUC, indicating that oral clearance is independent of dose for the dose range evaluated in this study. Urinary recovery data indicated that the efficacy of absorption was dose independent.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3593904     DOI: 10.1002/bdd.2510080308

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  15 in total

1.  Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS.

Authors:  Georgia Charkoftaki; Aristides Dokoumetzidis; Georgia Valsami; Panos Macheras
Journal:  Pharm Res       Date:  2012-07-04       Impact factor: 4.200

2.  Pharmacokinetic parameters of (R)-(-) and (S)-(+)-flurbiprofen in dairy bovines.

Authors:  L Igarza; A Soraci; N Auza; H Zeballos
Journal:  Vet Res Commun       Date:  2006-07       Impact factor: 2.459

3.  Stepwise determination of multicompartment disposition and absorption parameters from extravascular concentration-time data. Application to mesoridazine, flurbiprofen, flunarizine, labetalol, and diazepam.

Authors:  J G Wagner; D A Ganes; K K Midha; I Gonzalez-Younes; J C Sackellares; L D Olson; M B Affrime; J E Patrick
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

4.  Stereoselective disposition of flurbiprofen in uraemic patients.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

5.  Stereoselective disposition of flurbiprofen in normal volunteers.

Authors:  M P Knadler; D C Brater; S D Hall
Journal:  Br J Clin Pharmacol       Date:  1992-04       Impact factor: 4.335

6.  Serum protein binding of nonsteroidal antiinflammatory drugs: a comparative study.

Authors:  O Borgå; B Borgå
Journal:  J Pharmacokinet Biopharm       Date:  1997-02

7.  Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity.

Authors:  N K Zgheib; R F Frye; T S Tracy; M Romkes; R A Branch
Journal:  Br J Clin Pharmacol       Date:  2006-10-19       Impact factor: 4.335

8.  Plasma and cerebrospinal fluid pharmacokinetics of flurbiprofen in children.

Authors:  Elina Kumpulainen; Pyry Välitalo; Merja Kokki; Marko Lehtonen; Andrew Hooker; Veli-Pekka Ranta; Hannu Kokki
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

9.  Absorption of flurbiprofen in the fed and fasted states.

Authors:  J B Dressman; R R Berardi; G H Elta; T M Gray; P A Montgomery; H S Lau; K L Pelekoudas; G J Szpunar; J G Wagner
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

Review 10.  Clinical pharmacokinetics of flurbiprofen and its enantiomers.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1995-02       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.